Removal of TSE agent from plasma products manufactured in the United Kingdom
Authors:
- 21 November 2012
- journal article
- research article
- Published by Wiley in Vox Sanguinis
- Vol. 104 (4) , 299-308
Abstract
Background and Objectives The outbreak of vCJD in the UK leads to concern regarding the potential for human‐to‐human transmission of this agent. Plasma‐derived products such as albumin, immunoglobulin and coagulation factors were manufactured by BPL from UK plasma up until 1999 when a switch to US plasma was made. In the current study, the capacity of various manufacturing processes that were in use both prior to and after this time to remove the TSE agent was tested.Materials and Methods Small‐scale models of the various product manufacturing steps were developed. Intermediates were spiked with scrapie brain extract and then further processed. Samples were assayed for the abnormal form of prion protein (PrPSC) by Western blotting, and the reduction in the amount of scrapie agent determined.Results Many of the manufacturing process steps produced significant reduction in the scrapie agent. Particularly effective were steps such as ethanol fractionation, depth filtration, ion‐exchange and copper chelate affinity chromatography. Virus retentive filters, of nominal pore size 15 or 20 nm, removed >3 log. The total cumulative reduction capacity for individual products was estimated to range from 7 to 14 log. In the case of factor VIII (8Y), the total removal was limited to 3 log.Conclusion All the processes showed a substantial capacity to remove the TSE agent. However, this was more limited for the intermediate purity factor VIII 8Y which included fewer manufacturing steps.Keywords
This publication has 46 references indexed in Scilit:
- Efficacy and safety of a new immunoglobulin G product, Gammaplex®, in primary immunodeficiency diseasesClinical and Experimental Immunology, 2010
- Infectious prion protein in the filtrate even after 15nm filtrationBiologicals, 2010
- Removal of TSE agents by depth or membrane filtration from plasma productsBiologicals, 2010
- Resistance of Bovine Spongiform Encephalopathy (BSE) Prions to InactivationPLOS Pathogens, 2008
- The chemistry of copper binding to PrP: is there sufficient evidence to elucidate a role for copper in protein function?Biochemical Journal, 2008
- Prion removal by nanofiltration under different experimental conditionsBiologicals, 2008
- Prevalence of lymphoreticular prion protein accumulation in UK tissue samplesThe Journal of Pathology, 2004
- Partitioning of TSE infectivity during ethanol fractionation of human plasmaBiologicals, 2004
- Scrapie Removal using Planova®Virus Removal FiltersBiologicals, 2001
- Severely Heated Therapeutic Factor VIII Concentrate of High Specific ActivityVox Sanguinis, 1989